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Characterization of 111In-labeled 
Glucose-Dependent Insulinotropic 
Polypeptide as a Radiotracer for 
Neuroendocrine Tumors
Stefanie M. A. Willekens  1,2, Lieke Joosten1, Otto C. Boerman1, Maarten Brom  1 &  
Martin Gotthardt1
Somatostatin receptor targeting is considered the standard nuclear medicine technique for 
visualization of neuroendocrine tumors (NET). Since not all NETs over-express somatostatin 
receptors, the search for novel targets, visualizing these NETs, is ongoing. Many NETs, expressing low 
somatostatin receptor levels, express glucose-dependent insulinotropic polypeptide (GIP) receptors 
(GIPR). Here, we evaluated the performance of [Lys37(DTPA)]N-acetyl-GIP1-42, a newly synthesized GIP 
analogue to investigate whether NET imaging via GIPR targeting is feasible. Therefore, [Lys37(DTPA)]
N-acetyl-GIP1-42 was radiolabeled with 111In with specific activity up to 1.2 TBq/µmol and both in vitro 
and in vivo receptor targeting properties were examined. In vitro, [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
showed receptor-mediated binding to BHK-GIPR positive cells, NES2Y cells and isolated islets. In 
vivo, both NES2Y and GIPR-transfected BHK tumors were visualized on SPECT/CT. Furthermore, 
co-administration of an excess unlabeled GIP1-42 lowered tracer uptake from 0.7 ± 0.2%ID/g to 
0.6 ± 0.01%ID/g (p = 0.78) in NES2Y tumors and significantly lowered tracer uptake from 3.3 ± 0.8 to 
0.8 ± 0.2%ID/g (p = 0.0001) in GIPR-transfected BHK tumors. In conclusion, [Lys37(111In-DTPA)]N-acetyl-
GIP1-42 shows receptor-mediated binding in various models. Furthermore, both GIPR-transfected BHK 
tumors and NES2Y tumors were visible on SPECT/CT using this tracer. Therefore, [Lys37(111In-DTPA)]
N-acetyl-GIP1-42 SPECT seems promising for visualization of somatostatin receptor negative NETs.
Targeting of peptide hormone receptors, expressed on tumors, is a valuable tool for in vivo molecular imaging 
and radionuclide therapy of a variety of neuroendocrine tumors (NET). Successful tumor targeting relies on 
over-expression of target receptors on cancer cells when compared to their expression levels in healthy tissues1,2. 
Nowadays, somatostatin receptor targeting is a standard procedure for NET detection3–6 and radionuclide ther-
apy with 90Y- and 177Lu-labeled somatostatin analogues was proven beneficial to patients with NET7. However, 
not all NETs show elevated somatostatin receptor expression levels. Therefore, false negative results may occur 
in all NET types and somatostatin receptor imaging displays limited sensitivity for some types of NET, such as 
insulinomas (80–90% on 68Ga-DOTATATE PET)3,5,8–10 and medullary thyroid carcinoma (MTC) for which the 
detection rate is below 40–60%11.
A variety of alternative peptide receptors, such as cholecystokinin (CCK) receptors12, vasoactive intestinal 
peptide (VIP) receptors13 and glucagon-like peptide 1 (GLP-1) receptors (GLP-1R)14 are expressed on NET. 
Recent findings showed glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) expression in 
gastric, duodenal and bronchial NET15,16. Furthermore, approximately 90% of somatostatin receptor negative 
NET are GIPR positive16. In 2013, Sherman et al. pointed out that GIPR is a promising target for NET imaging 
and therapy due to its favorable expression pattern17 and the feasibility of GIPR targeting was shown in a GIPR 
over-expressing tumor model using a truncated GIP1-30 analogue18.
GIP is secreted from the intestinal K cells after nutrient ingestion19 and together with GLP-1, it enhances 
glucose-induced insulin secretion upon receptor binding on pancreatic beta cells, the so-called incretin effect20,21. 
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Since insulinomas are NETs derived from pancreatic beta cells, incretin receptors are expected to be ideal can-
didate receptors for insulinoma imaging. Indeed, GLP-1R targeting tracers, such as [68Ga]- or [111In]-labeled 
exendin, can be applied for non-invasive in vivo insulinoma detection22–24. However, since malignant insulino-
mas display differential GLP-1R and somatostatin receptor expression patterns25, detection rates of these tumors 
remain limited to 50% by scintigraphy. Interestingly, GLP-1R negative malignant insulinomas and a majority of 
somatostatin negative NETs express enhanced GIPR levels16, rendering this receptor an interesting target for NET 
and insulinoma imaging.
Since it was described that GIP1-30 exhibits reduced receptor binding affinity when compared to the 
full length peptide GIP1-4226,27, we have investigated the potential of a newly synthesized GIP1-42 analogue, 
[Lys37(111In-DTPA)]N-acetyl-GIP1-42 (Fig. 1) as a radiotracer for NET imaging, starting from the initial hypoth-
esis that a full-length peptide-based tracer might show improved characteristics for in vivo NET imaging when 
compared to GIP1-30. Therefore, we optimized the radiolabeling procedure and investigated its binding and inter-
nalization kinetics using GIPR-positive tumor cells (BHK-GIPR). Furthermore, we have also explored the tracers 
binding characteristics to NES2Y cells (a human beta cell-derived cell line, representing a more realistic model in 
terms of receptor expression)28 and isolated islets of Langerhans. Finally, subcutaneous BHK-GIPR and NES2Y 
tumors were visualized by SPECT after injection of [Lys37(111In-DTPA)]N-acetyl-GIP1-42.
Results
Radiolabeling and Serum Stability. [Lys37(DTPA)]N-acetyl-GIP1-42 could be labeled with 111In with a 
specific activity (now referred to as molar activity29) of up to 1.2 TBq/µmol. Radiochemical purity exceeded 95% 
as determined by RP-HPLC and ITLC, resulting in a final molar activity exceeding 142.5 MBq/µg or 712.5MBq/
nmol when starting with 150 MBq [111In]Cl3. Figure 2a shows the HPLC analysis of the labeling mixture. 
111In-EDTA eluted with a retention time of 3 minutes, whereas 111In labeled [Lys37(DTPA)]N-acetyl-GIP1-42 had a 
retention time of 14 minutes. After 12 minutes, a very small impurity (<2%) eluted from the column. Since GIP 
is known to be prone to inactivation by dipeptidyl peptidase IV (DPP IV), the stability of [Lys37(111In-DTPA)]
N-acetyl-GIP1-42 was analyzed in human serum. The results of this stability analysis are shown in Fig. 2b and c. 
Up to 4 hours of incubation in human serum, the [Lys37(111In-DTPA)]N-acetyl-GIP1-42 remained intact. After 
24 hours of incubation in human serum, 73% of the activity was still found as intact radiolabeled peptide, as 
determined by HPLC.
In vitro binding and internalization kinetics. The results of the apparent IC50 determination are 
shown in Fig. 3a. The apparent IC50 of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 is 4.8 µM (95% confidence inter-
val: 0.7–32.8 µM). However, the low internalization rate described below, render the observed value more likely 
to be a true IC50 rather than an apparent IC50. Figure 3b summarizes the binding and internalization kinet-
ics of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 by BHK-GIPR transfected cells and NES2Y cells as determined in 
vitro. Both cell lines displayed similar binding and internalization characteristics. After 1 hour, 0.6 ± 0.1% and 
0.6 ± 0.02% of the added [Lys37(111In-DTPA)]N-acetyl-GIP1-42 was bound to BHK-GIPR transfected cells and 
NES2Y cells, respectively. At this time point, the internalized fractions were 1.1 ± 0.1% and 1.5 ± 0.3%, respec-
tively. After 24 hours, the binding values had increased to 13.8 ± 1.7% and 8.6 ± 1.5%, respectively and the inter-
nalization values to 4.2 ± 0.6% and 4.7 ± 3.6% for BHK-GIPR and NES2Y cells, respectively. All values were 
corrected for non-specific binding, as determined by the addition of 25 µg unlabeled GIP1-42 which significantly 
reduced the binding and internalization at all time points indicating GIPR-mediated binding in both cell lines 
(p < 0.05). Figure 4 shows the in vitro binding characteristics of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 to 200 iso-
lated islets of C3H mice. After 24 hours, 0.22 ± 0.01 fmol [Lys37(DTPA)]GIP1-42 bound to the islets. Addition of 
25 µg unlabeled GIP1-42 reduced the binding to 0.03 ± 0.01 fmol, indicating specific binding of the tracer to the 
GIPR on the islets of Langerhans.
Peptide Dose Escalation Study. The effect of the peptide dose on tumor targeting was studied in BALB/c 
nude mice with subcutaneous BHK-GIPR tumors and the results are summarized in Fig. 5a. The [Lys37(DTPA)]
Figure 1. Amino acid sequence and molecular modifications of [Lys37(111In-DTPA)]N-acetyl-GIP1-42.
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N-acetyl-GIP1-42 dose had a pronounced effect on tumor uptake, which decreased significantly at peptide doses 
exceeding 0.2 µg (Fig. 5a and b). Highest tumor uptake of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 was observed at 
peptide doses ≤ 0.2 µg (0.04 nmol) per mouse: 5.2 ± 1.4%ID/g at 4 hours post-injection. Administration of 0.5 µg 
(0.1 nmol) as a peptide dose resulted in a significantly lower tumor uptake: 2.4 ± 0.7%ID/g (p = 0.008) (Fig. 5b). 
Four hours post-injection, [Lys37(111In-DTPA)]N-acetyl)GIP1-42 also showed uptake in various organs such as the 
lung, spleen, pancreas, liver, stomach and duodenum. The high uptake in the kidneys has been described as being 
the result of tubular reabsorption through the scavenger receptors cubilin and megalin, which is the case for many 
peptides30. As the kidney uptake of radiolabeled Lys37(111In-DTPA)]N-acetyl-GIP1-42 cannot be inhibited by an 
excess of unlabeled peptide, tubular reabsorption indeed appears to be the cause of the high kidney uptake. Raw 
data of this biodistribution study are shown in supplementary Table 1.
Biodistribution Studies. Figure 6a summarizes the biodistribution of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
in BALB/c nude mice bearing a subcutaneous BHK-GIPR transfected tumor. One hour after injection, highest 
tumor uptake was observed: 4.7 ± 0.8%ID/g. After 4 and 24 hours, tumor uptake decreased to 3.3 ± 0.8%ID/g 
and 2.0 ± 0.2%ID/g, respectively (Fig. 6a). Co-administration of an excess unlabeled GIP1-42 significantly lowered 
tumor uptake to 0.8 ± 0.2%ID/g (p = 0.0001) 4 hours after injection, indicating GIPR-mediated tumor uptake. 
One hour after injection, tumor uptake in NES2Y tumors was 0.7 ± 0.2%ID/g (Fig. 6b). Co-administration of an 
excess unlabeled GIP1-42 lowered tumor uptake to 0.6 ± 0.01%ID/g (p = 0.78) Raw data of these biodistribution 
studies are shown in supplementary Tables 2 and 3.
SPECT/CT imaging. One and four hours after injection of [Lys37(111In-DTPA)]N-acetyl-GIP1-42, BHK-GIPR 
transfected tumors were clearly visible on SPECT/CT (Fig. 7a and b). Co-injection of an excess unlabeled GIP1-42 
completely blocked tracer uptake in the BHK-GIPR transfected tumor (Fig. 7c). Also in mice bearing NES2Y 
tumors, clear tumor uptake was observed 1 hour after tracer injection (Fig. 8a and b). Furthermore, co-injection 
of an excess unlabeled GIP1-42 prevented tracer uptake in NES2Y tumors, suggesting GIPR-mediated tracer 
uptake in these tumors.
Figure 2. (a) Radiochemical purity analysis of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 as determined by HPLC, 
immediately after labeling. (b) HPLC profile of 111In-GIP after 24 hours of incubation in human serum. (c) 
Overview of stability behavior after various incubation times in human serum.
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Discussion
In this study, we investigated the potential of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 for NET detection. The tracer 
showed GIPR-mediated binding to BHK-GIPR positive cells and NES2Y cells, and to isolated islets in vitro. 
Optimal GIPR-mediated tumor targeting of BHK-GIPR positive tumors in vivo, was observed 1 hour post injec-
tion using a peptide dose of 0.2 µg (0.04 nmol). Furthermore, both BHK-GIPR transfected tumors and NES2Y 
tumors were visualized by SPECT.
It has been described that C-terminally truncated GIP analogues, such as GIP1-30, exhibit reduced receptor 
binding affinity when compared to intact GIP1-42, while retaining their full insulinotropic effect26,27. Since the goal 
of this study was to apply the analogue for in vivo imaging, high receptor affinity should be preserved rather than 
biological activity. Therefore, we selected GIP1-42 as a basis for our radiotracer. Another point of consideration 
while designing a GIPR targeting radiotracer, is the susceptibility of the native peptide to DPP IV degradation31. 
Since it was shown that several N-terminal modifications showed increased half-life in vitro32,33, we acetylated the 
N-terminal tyrosine residue to obtain a better DPP IV degradation-resistant tracer. Indeed, we observed that the 
tracer remained stable in serum for at least 4 hours after incubation and even after 24 hours of incubation 73% of 
the tracer remained intact.
In order to obtain high quality images, high target-to-background ratios are required. Tracer metabolites labe-
led with a radiometal via a chelator, can be trapped in the lysosomes upon tracer internalization and degradation, 
resulting in enhanced tracer accumulation in the target cells23,34. Therefore, we investigated tracer internaliza-
tion rates in vitro. Internalization kinetics of the tracer were comparable and relatively slow: after 24 hours, both 
BHK-GIPR positive and NES2Y cell showed similar internalization rates of 4.2 ± 0.6%ID/g and 4.7 ± 3.6%ID/g, 
Figure 3. In vitro characterization (a) Competition binding assay (apparent IC50) of [Lys37(DTPA)]GIP1-42 on 
NES2Y cells. [Lys37(111In-DTPA)]N-acetyl-GIP1-42 was used as a radiotracer (b) binding and internalization 
kinetics of 111In-GIP in BHK-GIPR positive cells and NES2Y cells. Cell bound and internalized fractions are 
corrected for non-specific binding and accumulation, as determined by co-incubation with an excess unlabeled 
GIP1-42.
Figure 4. Binding of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 to isolated islets. The solid bar represents binding of 
[Lys37(111In-DTPA)]N-acetyl-GIP1-42. The white bar represents binding of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
in the presence of an excess GIP1-42.
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respectively. Interestingly, the majority of the tracer was bound to the cell surface in both cell lines. These obser-
vations could be explained by very recent findings of Ismail et al. indicating that N-terminal acetylation of the 
peptide hampers receptor internalization35.
In BHK-GIPR positive tumors, GIP1-42 doses lower than 0.5 µg (0.1 nmol) resulted in maximal tumor accumu-
lation. This indicates that administration of higher peptide doses results in partial saturation of the GIPR in vivo. 
However, since the tracer could be labeled with a specific activity up to 1.2 TBq/µmol, administration of an activ-
ity dose for imaging dose is still feasible. For in vivo SPECT imaging, high tumor-to-blood ratios are required. 
Figure 5. (a) Peptide dose escalation study in BALB/c nude mice with subcutaneous BHK-GIPR tumors. 
Values are expressed as percentage injected dose per gram tissue (%ID/g) (n = 5). (b) Tumor uptake of 
[Lys37(111In-DTPA)]N-acetyl-GIP1-42 using different peptide doses. Tumor uptake was significantly higher 
(**p = 0.008) at peptide doses smaller than 0.5 µg (0.1 nmol).
Figure 6. (a) Biodistribution study of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 in BALB/c nude mice bearing 
subcutaneous BHK-GIPR tumors at 1, 4 and 24 hours after tracer injection. Values are expressed as percentage 
injected dose per gram tissue (%ID/g) (n = 5). Blocking was performed by co-injected of 25 µg unlabeled GIP1-42 
(n = 5). (b) Biodistribution study of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 in BALB/c nude mice bearing 
subcutaneous NES2Y tumors, 1 hour after tracer injection. Values are expressed as percentage injected dose per 
gram tissue (%ID/g) (n = 5). Blocking was performed by co-injection of 25 µg unlabeled GIP1-42 (n = 2).
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However, since tracer uptake in the blood was still very low at a peptide dose of 0.2 µg, we selected this dose as the 
optimal dose for in vivo imaging since it resulted in the highest absolute tumor uptake.
Although [Lys37(111In-DTPA)]N-acetyl-GIP1-42 showed high and specific tumor uptake in GIPR-transfected 
GIPR tumors, tumor uptake in NES2Y tumors was lower and co-injection of an excess unlabeled GIP1-42 did 
not result in significantly lower tracer uptake. This clear difference in tracer uptake might be explained by the 
completely different origin and purpose of both cell lines. While the BHK-GIPR cell line was created to express 
artificially high receptor levels, the NES2Y cells are derived from patients with congenital hyperinsulinism of 
infancy (28). Since these cells do not overexpress the target receptor and it is known that the natural expression 
levels of the GIPR are much lower compared to its brother incretin peptide GLP-136, the lower uptake is to be 
expected. As for the blocking study, the small size of the blocking group (n = 2) impairs generation of repre-
sentative results. Therefore, the obtained significance level (p = 0.78) might be distorted. On the SPECT images 
however, tracer accumulation was observed in NES2Y tumors but was no longer observed after co-injection of 
an excess unlabeled GIP1-42 (Fig. 8b), suggesting specific tumor targeting. Nevertheless, several tracer charac-
teristics might be optimized to further improve tumor targeting. Firstly, other N-terminal modifications than 
acetylation, such as glucitol or pyroglutamil insertion, have been shown to improve the half-life of the peptide 
in the presence of DPP IV32,33 and might also result in higher internalization rates. Secondly, receptor bind-
ing and internalization might increase with longer circulation times. As shown in our biodistribution studies, 
[Lys37(111In-DTPA)]N-acetyl-GIP1-42 is cleared from the blood very rapidly, hampering longer tracer circulation 
and thus higher tumor uptake. Several methods such as PEGylation, multimerization or introduction of free fatty 
acid tails might increase circulation time37 and thereby tracer accumulation in the tumor. However, a good bal-
ance between tracer retention in blood and tracer targeting dynamics has to be found in order to obtain favorable 
target-to-background ratios for in vivo imaging.
[Lys37(111In-DTPA)]N-acetyl-GIP1-42 was produced at a high molar activity and showed receptor medi-
ated binding to various GIPR expressing cells in vitro. Subcutaneous BHK-GIPR positive tumors showed 
GIPR-mediated tracer accumulation with optimal in vivo targeting 1 hour post-injection, at a peptide dose of 
0.2 µg (0.04 nmol). Furthermore, although very low, uptake of a GIP-based tracer was demonstrated for the first 
time in a human beta-cell derived tumor. Unfortunately, specificity of tracer binding could not be shown due to 
the small size of the blocking group. In conclusion, [Lys37(111In-DTPA)]N-acetyl-GIP1-42 shows promising results 
as a radiotracer for NET imaging. However, the initial working hypothesis that a full-length peptide-based tracer 
might show improved characteristics for in vivo NET imaging when compared to GIP1-30 could not be confirmed.
Methods
Radiolabeling. [Lys37(DTPA)]N-acetyl-GIP1-42 (MW = 5422 g/mol) and GIP1-42 (MW = 5046.7 g/mol) were 
purchased from Peptide Specialty Laboratories (PSL GmbH, Heidelberg, Germany). DTPA was conjugated to 
the ε-amino group of the Lysine (K37) and the N-terminal tyrosine was acetylated to reduce its susceptibility to 
Figure 7. Maximum intensity projection (MIP) SPECT/CT images of a BALB/c nude mouse bearing a 
subcutaneous BHK-GIPR tumor 1 hour after injection (a), 4 hours after injection (b) and 4 hours after injection 
and co-injection with 25 µg unlabeled GIP1-42 (c).
www.nature.com/scientificreports/
7SCIeNTIfIC REPoRTS |  (2018) 8:2948  | DOI:10.1038/s41598-018-21259-3
endopeptidases (Fig. 1). [Lys37(DTPA)]GIP1-42 was dissolved in 0.5 M MES (2-(N-morpholino)ethanesulfonic acid) 
buffer, pH 5.5 and stored at 4 °C until use. 150 MBq [111In]Cl3 (Mallinckrodt Pharmaceuticals, ‘s Hertogenbosch, 
The Netherlands) was added to 1 µg [Lys37(DTPA)]N-acetyl-GIP1-42 together with 5 volumes of 0.5 M MES buffer 
(1:5 relation 111In:buffer), pH 5.5 and incubated for 20 min at room temperature (RT). After incubation, EDTA 
(Sigma Aldrich, St. Louis, MO, USA) and Tween80 (Sigma Aldrich) were added to a final concentration of 5 mM 
and 0.1%, respectively. The labeling mixture was purified by solid-phase extraction using a hydrophilic-lipophilic 
balance (HLB) cartridge (30 mg, Waters Oasis, Milford, MA, USA), to eliminate unincorporated 111In. The car-
tridge was activated with 1 ml ethanol, washed with 2 ml water and conditioned with 1 ml of 0.5 M MES, pH 5.5. 
Subsequently, the cartridge was loaded with the labeling mixture, washed with 1 ml 0.5 M MES and 2 ml water 
and [Lys37(111In-DTPA)]N-acetyl-GIP1-42 was eluted from the cartridge with 200 µL 100% ethanol. For in vivo use, 
purified labeled peptide was diluted in phosphate buffered saline (PBS), 0.5% bovine serum albumin (BSA) (w/v) to 
obtain a final ethanol concentration of less than 10%. Radiochemical purity of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
was determined by instant thin-layer chromatography (ITLC) (ITLC-SG, Agilent Technologies, Lake Forest, CA, 
USA), using 0.1 M EDTA in 0.1 M NH4Ac (Sigma Aldrich), pH 5.5 as a mobile agent and by reversed-phase high 
performance liquid chromatography (RP-HPLC) using an Eclipse XDB C18 column (Agilent Technologies). The 
column was eluted with 0.1% trifluoroacetic acid (TFA) in H2O (0-5 minutes) followed by a linear gradient from 3% 
to 100% acetonitrile with 0.1% TFA over 10 minutes (flow rate: 1 ml/minute).
Serum Stability Analysis. For the serum stability analysis, [Lys37(DTPA)]N-acetyl-GIP1-42 was labeled with 
[111In]Cl3 at a specific activity of 27 GBq/µmol. Radiochemical purity of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 directly 
after labeling was determined by ITLC-SG (Agilent Technologies) and RP-HPLC as described above. A sample of the 
Figure 8. SPECT/CT (a) and SPECT (b) of a BALB/c nude mouse bearing a subcutaneous NES2Y tumor, 
1 hour after injection and SPECT/CT (c) and SPECT (d) after co-injection with 25 µg unlabeled GIP1-42.
www.nature.com/scientificreports/
8SCIeNTIfIC REPoRTS |  (2018) 8:2948  | DOI:10.1038/s41598-018-21259-3
labeling mixture was incubated in human serum (1:10) at 37 °C. After 1, 2, 4 and 24 hours, a sample was taken and 
serum proteins were precipitated by adding acetonitrile. This mixture was centrifuged and after dilution, the radi-
ochemical purity of the compound in the supernatant was analyzed using ITLC and RP-HPLC as described above.
Cell Culture. Baby hamster kidney cells, transfected with the human GIP (BHK-GIPR cells) were maintained 
in DMEM Glutamax (cat. Nr. 6195, GIBCO, BRL Life Sciences Technologies, Bleiswijk, The Netherlands) sup-
plemented with 10% fetal bovine serum (FCS), (HyClone, Celbio, Logan, UT, USA) and 1 mg/ml G418, in a 
humidified atmosphere containing 5% CO2 at 37 °C. The human beta cell line NES2Y was cultured as described 
previously (28). Briefly, cells were maintained in RPMI 1640 (R0883, GIBCO) supplemented with 10% FCS, 
(HyClone, Celbio), 2 mM L-glutamine (Sigma Aldrich), 100 U/ml penicillin (Sigma Aldrich) and 100 µg/ml 
streptomycin (Sigma Aldrich) (complete RPMI), in a humidified atmosphere containing 5% CO2 at 37 °C.
IC50 Determination. The 50% inhibitory concentration (IC50) of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
was determined using NES2Y cells. NES2Y cells were seeded at a density of 200,000 cells/well in 24-well plates 
and incubated overnight at 37 °C. The cells were washed with binding buffer (RPMI + 0.5% BSA (w/v)) and 
[Lys37(DTPA)]N-acetyl-GIP1-42 was added at a final concentration ranging from 1.0 – 100 µM along with radio-
labeled [Lys37(111In-DTPA)]N-acetyl-GIP1-42 (4.6 kBq = 2.7 fmol). After o/n (15 h) incubation at 37 °C, cells were 
washed with binding buffer and cell-associated activity was measured in a well type gamma counter (Wallac 2480 
wizard, Perkin Elmer). Under these conditions, internalization may occur. We therefore designate the results of 
this competitive binding assay as “apparent IC50” values rather than IC50.
Internalization kinetics. The internalization kinetics of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 was deter-
mined as previously described38 using BHK-GIPR transfected cells and NES2Y cells. BHK-GIPR transfected cells 
and NES2Y cells were seeded in 24-well plates with a density of 50,000 and 200,000 cells/well, respectively and 
incubated overnight at 37 °C. Cells were washed with binding buffer and incubated with approximately 1.6 kBq 
[Lys37(111In-DTPA)]N-acetyl-GIP1-42 (2.7 fmol) for 1, 2, 4 and 24 h at 37 °C. After incubation, cells were washed 
twice with binding buffer. To determine the surface-bound fraction, ice-cold acid buffer (0.1 M acetic acid, 
154 mM NaCl, pH 2.5) was added and cells were incubated for 10 minutes at 4 °C. After washing the cells twice 
with binding buffer to makes sure that all surface-bound tracer was removed from the cells, the cell-associated 
activity was measured in a well type gamma counter. After removal of the surface-bound activity, the inter-
nalized fraction was represented by the remaining cell-associated activity. The internalized fraction (remaining 
cell-associated activity after acid wash) and the receptor bound fraction (activity removed by acid wash) were 
determined in a well-type gamma counter.
Animals. All animal experiments were approved by the Animal Welfare Body of the Radboud University, 
Nijmegen, The Netherlands and carried out in accordance with their guidelines. Six to eight weeks old, female 
BALB/c nude mice and C3H mice were purchased from Janvier labs (Le Genest Saint Isle, France). For all in vivo 
experiments, 6-8 weeks old female BALB/c nude mice were injected subcutaneously in the right shoulder with 
0.2 ml of a 2.5 × 107 cells/ml suspension of BHK-GIPR transfected cells or with 0.2 ml of a 2.5 × 107 cells/ml sus-
pension of NES2Y cells mixed with matrigel (2:1) in the right shoulder. When the tumor reached a diameter of 
2-5 mm, mice were randomly divided in groups.
Islet Isolation. Islets of Langerhans were isolated from donor C3H mice by collagenase digestion as follows. 
Mice were euthanized by CO2/O2 suffocation and 2 ml of ice cold RPMI 1640 containing 1 mg/ml collagenase type V 
(Sigma Aldrich) were infused via the pancreatic duct in situ. After dissection, the perfused pancreata were collected 
in serum free medium containing collagenase and kept on ice until digestion. Pancreata were digested for 12 min at 
37 °C. Digestion was stopped by adding RPMI medium containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicil-
lin and 100 U/ml streptomycin (complete RPMI). After washing, digested pancreata were passed through a mesh. 
Afterwards, islets were purified on a discontinuous Ficoll gradient (densities: 1.108; 1.096; 1.037; Cellgro by Mediatech 
Inc, Manassas, VA, USA) by centrifugation at 625 × g for 16 min without brake. Islets were collected from the intersec-
tion of the second and third layer and remaining Ficoll was removed by washing with complete RPMI. Isolated islets 
were cultured overnight in complete RPMI medium in a humidified atmosphere containing 5% CO2 at 37 °C.
In Vitro Binding to Isolated Islets. After overnight recovery from the isolation procedure, islets from 
the donor C3H mice were collected, counted and resuspended in complete RPMI. After transwell saturation 
using binding buffer, islets were transferred to 24 well transwell plates (200 islets per transwell) (Corning Inc. 
Tewksbury, MA, USA) and washed with binding buffer. Subsequently, approximately 8 kBq [Lys37(111In-DTPA)]
N-acetyl-GIP1-42 (13.5 fmol) was added followed by incubation for 24 hours at 37 °C. To investigate the 
GIPR-mediated binding, 25 µg of unlabeled GIP1-42 was added together with [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
in a separate set of wells. After incubation, islets were washed extensively with binding buffer and islet-associated 
radioactivity was measured in a well type gamma counter.
Peptide Dose Escalation Study. To determine the optimal peptide dose of [Lys37(DTPA)]N-acetyl-GIP1-42, 
BHK-GIPR transfected tumor bearing BALB/c nude mice (n = 5/group) were injected intravenously with approx-
imately 3 MBq [Lys37(111In-DTPA)]N-acetyl-GIP1-42 (0.05 µg) in the tail vein and were co-injected with escalating 
amounts of unlabeled [Lys37(DTPA)]N-acetyl-GIP1-42 (0.05 µg – 1.95 µg), resulting in final peptide doses ranging 
from 0.1 to 2 µg/mouse (0.02 – 0.4 nmol/mouse) (5 groups, n = 5/group). Four hours after injection, mice were 
euthanized by CO2/O2 suffocation and tumors and other relevant tissues (heart, muscle, lung, spleen, pancreas, 
kidney, liver, stomach and duodenum) were dissected, weighed and measured in a well type gamma counter. The 
percentage injected dose per gram of tissue (%ID/g) was determined for each tissue.
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Biodistribution Studies. BALB/c nude mice bearing BHK-GIPR transfected tumors were injected intra-
venously with approximately 3 MBq (peptide dose 0.2 µg = 0.04 nmol) of [Lys37(111In-DTPA)]N-acetyl-GIP1-42 
via the tail vein. At various time points after injection (1, 4 and 24 hours), mice were euthanized by CO2/O2 
suffocation and blood, tumor and other relevant tissues were dissected, weighed and measured in a well type 
gamma counter. The percentage injected dose per gram (%ID/g) was calculated for each tissue. To determine 
whether the GIP1-42 uptake was GIPR mediated, 25 µg of unlabeled GIP1-42 was co-injected in a separate group 
(n = 5) and mice were euthanized four hours post-injection. BALB/c nude mice bearing NES2Y tumors (n = 5) 
were injected intravenously with approximately 3 MBq (peptide dose 0.2 µg = 0.04 nmol) of [Lys37(111In-DTPA)]
N-acetyl-GIP1-42 via the tail vein. One hour after injection, mice were euthanized by CO2/O2 suffocation and 
blood, tumor and other relevant tissues were dissected, weighed and measured in a well type gamma counter. The 
percentage injected dose per gram (%ID/g) was determined for each tissue. To determine whether the GIP1-42 
uptake was GIPR mediated, 25 µg of unlabeled GIP1-42 was co-injected in a separate group (n = 2) and mice were 
euthanized one hours post-injection.
SPECT/CT. One (BHK-GIPR tumors and NES2Y tumors) or four (BHK-GIPR tumors)hours (n = 2/group) 
prior to SPECT imaging, BALB/c nude mice were injected intravenously in the tail vein with 20.6 ± 0.7 MBq 
[Lys37(111In-DTPA)]N-acetyl-GIP1-42 (peptide dose 0.2 µg ( = 0.04 nmol) in 200 µl injection fluid). SPECT/
CT scans were acquired on a dedicated small animal SPECT/CT scanner (U-SPECT-II, Milabs, Utrecht, The 
Netherlands) with a 1.0 mm mouse collimator, using 36 bed positions and an acquisition time of 30 minutes 
(BHK-GIPR tumors) or 45 minutes (NES2Y tumors). After SPECT acquisition, CT (65 kV, 615 µA, 1 bed posi-
tion) was acquired as an anatomical reference. SPECT scans were reconstructed using U-SPECT-II reconstruc-
tion software (U-SPECT-Rec, Milabs, Utrecht, The Netherlands) with the following settings: selection of the lower 
111In photopeak (152–183 keV), corrected for two backgrounds (135–151 keV and 184–211 keV), pixel based 
OSEM, voxel size 0.4 mm3 and 1 iteration over 16 subsets.
Statistics. All values are expressed as mean ± standard deviation (SD). Statistical analysis was performed 
using unpaired two-tailed t-test using GraphPad Prism v5.03 (GraphPad Softwarem Inc., San Diego, CA, USA). 
The level of significance was set at p < 0.05.
Ethical approval. All animal experiments were approved by the Animal Welfare Body of the Radboud 
University, Nijmegen, The Netherlands and carried out in accordance with their guidelines.
Data availability statement. all data are available at the department of Nuclear medicine of the Radboud 
University medical center, Nijmegen.
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